Rheumatoid Arthritis

Rates of osteoporosis and osteoporotic fractures have fallen significantly among patients with rheumatoid arthritis over the past 24 years, according to a single-center study published in RMD Open.

Switching from a TNF inhibitor to upadacitinib leads to significantly better outcomes in rheumatoid arthritis vs. cycling TNF inhibitors or switching to another mechanism of action, according to data published in Advances in Therapy.

The implementation of treat-to-target approaches for rheumatoid arthritis remains largely suboptimal, but could be improved with telehealth and other measures, according to data published in Arthritis Care & Research.

Infliximab biosimilar uptake increased by no more than just 5% annually following the release of its first two biosimilars, but then shot up by 13% to 16% for most patients after a third option emerged, according to data.

Upadacitinib shows superior clinical, radiographic and patient-reported outcomes in RA, and has a more favorable risk-benefit profile, compared with methotrexate over 5 years, according to data published in Arthritis Research & Therapy.

Biosimilar medications — drugs developed to be very similar, but not identical, to an FDA-approved biologic — were intended to play a vital role in increasing affordable options for patients struggling with a range of chronic conditions.

Nearly all biologic and targeted synthetic disease-modifying antirheumatic drugs come with infection or malignancy warnings from U.S. or European regulatory agencies, according to a study published in Drug Safety.

The use of machine learning models to predict treatment response in rheumatoid arthritis is increasing, though approximately 80% show “unclear and high risk of bias,” according to data published in Seminars in Arthritis and Rheumatism.

Systemic immune-inflammation index levels may be used to predict all-cause and cardiovascular mortality among patients with rheumatoid arthritis, according to data published in Scientific Reports.

Former New York Yankees center fielder Bernie Williams is sharing resources for patients with interstitial lung disease as a tribute to his late father, who lost his battle with idiopathic pulmonary fibrosis in 2001.